-
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-18 Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M. Soliman, Michael Chen, Byron Padilla, Frank Behrens
-
Long-Term Efficacy Following Intra-articular Injection of Carboxymethyl-chitosan, a New Product Class for Knee Osteoarthritis: Results from an Observational Study in Germany Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-18 Nils A. Lynen, Christoph Eichhorn, Nicolas Portelange, Mickaël Chausson, Wim Weyenberg
-
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-18 Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, Byron Padilla, Alan Kivitz
-
Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-15 Xenofon Baraliakos, Annette E. Szumski, Kenneth K. Kwok, Bonnie Vlahos, Cecilia E. Borlenghi
-
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-15 Richard B. Warren, Iain B. McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Philip J. Mease
-
Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-11 Louis Bessette, Jonathan Chan, Andrew Chow, Larissa Lisnevskaia, Nicolas Richard, Pierre-Andre Fournier, Dalinda Liazoghli, Tanya Girard, Derek Haaland
-
Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2024-04-01
Abstract Introduction Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for half of the patient population. This study aims to identify biomarkers for early evaluation of imrecoxib
-
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-06 Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes
-
Assessment of Patient–Physician Interactions in Psoriatic Arthritis: National Results of the ASSIST Study Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-06 Fabio Massimo Perrotta, Rossana Scrivo, Salvatore D’Angelo, Silvia Scriffignano, Andrea Delle Sedie, Laura Coates, Ennio Lubrano
-
The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-04 Piero Ruscitti, Giulia Cataldi, Martina Gentile, Alice Dionisi, Paola Volpe, Annacarla Finucci, Lucrezia Verardi, Claudia Di Muzio, Noemi Italiano, Eleonora Celletti, Myriam Di Penta, Ilenia Di Cola, Alessandra Marrelli, Alessia Alfonsi, Francesco Delle Monache, Francesco Cipollone, Marco Gabini, Paola Cipriani
-
Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-04
Abstract Introduction ABP 501 was an adalimumab (ADA) biosimilar approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). In this retrospective study, we aimed to examine the treatment patterns of ABP 501 among patients with these IMIDs using German and French pharmacy claims databases. Methods
-
Neutrophilic Activity Biomarkers (Plasma Neutrophil Extracellular Traps and Calprotectin) in Established Patients with Rheumatoid Arthritis Receiving Biological or JAK Inhibitors: A Clinical and Ultrasonographic Study Rheumatol. Ther. (IF 3.8) Pub Date : 2024-03-02 Beatriz Frade-Sosa, Andrés Ponce, Estíbaliz Ruiz-Ortiz, Noemí De Moner, María J. Gómara, Ana Belén Azuaga, Juan C. Sarmiento-Monroy, Rosa Morlà, Virginia Ruiz-Esquide, Laura Macías, Nuria Sapena, Lola Tobalina, Julio Ramirez, Juan D. Cañete, Jordi Yague, Josep M. Auge, José A. Gomez-Puerta, Odette Viñas, Isabel Haro, Raimon Sanmarti
-
Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-28 Vinod Chandran, Louis Bessette, Carter Thorne, Maqbool Sheriff, Proton Rahman, Dafna D. Gladman, Sabeen Anwar, Jennifer Jelley, Anne-Julie Gaudreau, Manprit Chohan, John S. Sampalis
-
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-28 Pushpike Thilakarathne, Agata Schubert, Steve Peterson, Wim Noel, Barkha P. Patel, Fareen Hassan
-
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-22 Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P. Kollmeier, Natalie J. Shiff, Chenglong Han, May Shawi, William Tillett, Philip J. Mease
-
Reproductive Effect by Rheumatoid Arthritis and Related Autoantibodies Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-20 Ping-Fen Li, Shan Li, Peng-Sheng Zheng
-
Reliability Exercise of Ultrasound Salivary Glands in Sjögren’s Disease: An International Web Training Initiative Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-19 Baptiste Quéré, Alain Saraux, Guillermo Carvajal-Alegria, Dewi Guellec, Gaël Mouterde, Christophe Lamotte, Daniel Hammenfors, Malin Jonsson, Sung-Eun Choi, Min Hong-Ki, Alja Stel, Benjamin A. Fisher, Mark Maybury, Benedikt Hofauer, Francesco Ferro, Vera Milic, Dana Direnzo, Valérie Devauchelle-Pensec, Sandrine Jousse-Joulin
-
Thermography at the Elbow Among Patients with Rheumatoid Arthritis: A Comparison with Ultrasound-Detected Joint Inflammation Findings Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-15 York Kiat Tan, Rehena Sultana, Julian Thumboo
-
Anemia and Low Body Mass Index in Axial Spondyloarthritis: Results from ChinaSpA, the Chinese Spondyloarthritis Registry Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-13 Hailong Li, Qingyang Li, Xinwang Duan, Shangzhu Zhang, Yanhong Wang, Jian Xu, Qin Li, Lijun Wu, Zhenbiao Wu, Min Yang, Shengyun Liu, Jinmei Su, Mengtao Li, Xiaofeng Zeng, Xiang Gao
-
Safety and Efficacy of Hybrid Cooperative Complexes of Sodium Hyaluronate and Sodium Chondroitin for the Treatment of Patients with Symptomatic Knee Osteoarthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-12 Cristiano Sconza, Dario Romano, Dalila Scaturro, Giulia Letizia Mauro, Giulia Leonardi, Angelo Alito, Stefano Respizzi, Elizaveta Kon, Berardo Di Matteo
-
Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-12
Abstract Introduction Data assessing longer-term real-world effectiveness and treatment patterns with upadacitinib (UPA), a Janus kinase inhibitor, in rheumatoid arthritis (RA) are lacking. We assessed improvement in clinical and patient-reported outcomes and treatment patterns for up to 12 months among adult patients with RA initiating UPA. Methods Data were collected from the CorEvitas® RA Registry
-
Emerging Role of Interleukin-38 (IL-38) in the Development of Rheumatoid Arthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-05 Shengxiang Liang, Liting Chen, Ruilan Liang, Jiayi Ling, Minghui Hou, Song Gao, Minglin Ou, Min Yang
-
Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-03 Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaçi, Anja Plenske, Pascal Klaus, Thomas Meng
-
Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-01 Qin-Yi Su, Hao-Nan Zhou, Guo-Mei Xia, Rui-Yuan Zhang, Hong-Yuan Tian, Chang Su, Yu-Xin Liu, He-Yi Zhang, Ting Cheng, Yue-Hong Huo, Qian Li, Sheng-Xiao Zhang
-
Social Listening in Gout: Impact of Proactive vs. Reactive Management on Self-Reported Emotional States Rheumatol. Ther. (IF 3.8) Pub Date : 2024-01-22 Maurice Flurie, Monica Converse, E. Robert Wassman, Brian LaMoreaux, N. Lawrence Edwards, Colton Flowers, Daniel Hernandez, Helen W. Hernandez, Gary Ho, Christopher Parker, Christopher DeFelice, Maria Picone
-
The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany Rheumatol. Ther. (IF 3.8) Pub Date : 2024-01-22 Bo Ding, Marc Pignot, Elena Garal-Pantaler, Beate Villinger, Sebastian Schefzyk, Barnabas Desta, Heide A. Stirnadel-Farrant, Andreas Schwarting
-
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Rheumatol. Ther. (IF 3.8) Pub Date : 2024-01-22 Philip J. Mease, Pamela Young, Lara Fallon, Rajiv Mundayat, Oluwaseyi Dina, Taylor Blachley, Nicole Middaugh, Alexis Ogdie
-
Real-World Burden of Immunosuppressant-Treated Lupus Nephritis: A German Claims Database Analysis Rheumatol. Ther. (IF 3.8) Pub Date : 2024-02-01 Elena Garal-Pantaler, Michael Schultze, Mary Elizabeth Georgiou, Marc Pignot, Kerry Gairy, Jacob N. Hunnicutt
-
Impact of the COVID-19 Pandemic on People Living with Rheumatoid Arthritis: Experiences and Preferences in Accessing Healthcare Across Five Countries Rheumatol. Ther. (IF 3.8) Pub Date : 2024-01-13 Alain Saraux, Licia Maria Henrique da Mota, Sanjay Dixit, Allan Gibofsky, Tsukasa Matsubara, Amy Mulvey, Cheryl Koehn, Mahta Mortezavi, Michelle Segovia, Meriem Kessouri
-
Characteristics of COVID-19 and Impact of Disease Activity in Patients with Adult-Onset Still’s Disease Rheumatol. Ther. (IF 3.8) Pub Date : 2024-01-06
Abstract Introduction This study aimed to characterize the morbidity, hospitalization, and mortality rates among patients with adult-onset Still’s disease (AOSD) affected by coronavirus disease 2019 (COVID-19) and explore the impact of COVID-19 on the disease activity of AOSD. Methods Data on the clinical and demographic characteristics, COVID-19-related symptoms, and outcomes were retrospectively
-
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years Rheumatol. Ther. (IF 3.8) Pub Date : 2024-01-05
Abstract Introduction Upadacitinib (UPA) is a Janus kinase inhibitor that has demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA) with an acceptable safety profile. We investigated laboratory parameter changes in UPA RA clinical trials. Methods Pooled data from six randomized trials in the SELECT phase 3 program were included. Key laboratory parameters and safety data were measured
-
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant Infection Rheumatol. Ther. (IF 3.8) Pub Date : 2024-01-04 Xiaowei Zhang, Yifei Li, Chunqing Dai, Yaya Chu, Chaoqi Luan, Guihong Wang
Introduction The purpose of this study was to investigate whether the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has a similar effectiveness and safety profile in patients with rheumatic and musculoskeletal diseases (RMDs) and healthy controls (HCs). Methods Between August 10, 2021 and September 30, 2021, 134 HCs and 269 patients with RMDs were recruited. All participants
-
The Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities Rheumatol. Ther. (IF 3.8) Pub Date : 2023-12-18 Daniele Mauro, Giulio Forte, Denis Poddubnyy, Francesco Ciccia
-
Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2023-12-09 Megan M. Simonds, Samuel T. Freer, Lina Al-Jaberi, AnneMarie C. Brescia
-
Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis Rheumatol. Ther. (IF 3.8) Pub Date : 2023-12-06 Jeffrey R. Curtis, Paul Emery, Bryan Downie, Yan Zhong, Jinfeng Liu, Ling Han, Rachael E. Hawtin, Gerd Rüdiger Burmester
-
Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2023-12-02 Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch
-
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2023-11-20 Andrea Rubbert-Roth, Adriana M. Kakehasi, Tsutomu Takeuchi, Marc Schmalzing, Hannah Palac, Derek Coombs, Jianzhong Liu, Samuel I. Anyanwu, Ralph Lippe, Jeffrey R. Curtis
-
Efficacy, Safety and the Lymphocyte Subset Changes of Low-Dose IL-2 in Patients with Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis Rheumatol. Ther. (IF 3.8) Pub Date : 2023-11-19 Qinyi Su, Xinmiao Wang, Yongzhi Li, Jiexiang Zhang, Cairui Bai, Xuechun Wang, Liu Yang, Jingting Zhang, Sheng-Xiao Zhang
-
Cross-Sectional and Longitudinal Associations of Comorbidities with Knee Symptoms and Radiographic Abnormalities of Osteoarthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2023-11-18 Xiaoxi Li, Feng Pan, Rui Zhu, Liru Ge, Xiaoyue Zhang, Xiangrui Wen, Jiantao Zhou, Jiale Cheng, Faming Pan, Guoqi Cai
Introduction This study aimed to investigate the associations of comorbidities with knee symptoms and radiographic abnormalities of osteoarthritis (OA). Methods Participants were from the Osteoarthritis Initiative. Comorbidities were identified at baseline using the modified Charlson Comorbidity Index. For both knees, symptoms were assessed annually from baseline to 48 months using the Western Ontario
-
Epidemiology of Sjögren’s: A Systematic Literature Review Rheumatol. Ther. (IF 3.8) Pub Date : 2023-11-10 Eleanor Thurtle, Alice Grosjean, Monia Steenackers, Katharina Strege, Giovanna Barcelos, Pushpendra Goswami
-
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2023-11-10 Jeffrey R. Curtis, Vibeke Strand, Steven J. Golombek, George A. Karpouzas, Lixia Zhang, Angus Wong, Krishna Patel, Jennifer Dines, Viatcheslav R. Akmaev
-
Endovascular Interventional Procedure is a Significant Risk Factor of Postsurgical Gout: A Retrospective Cohort Study Rheumatol. Ther. (IF 3.8) Pub Date : 2023-11-06 Shunjie Hu, Zitao Wang, Peiyu Zhang, Huaxiang Wu, Xiaoyong Lu
-
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials Rheumatol. Ther. (IF 3.8) Pub Date : 2023-11-05 Gustavo Citera, Rakesh Jain, Fedra Irazoque, Hugo Madariaga, David Gruben, Lisy Wang, Lori Stockert, Karina Santana, Abbas Ebrahim, Dario Ponce de Leon
-
Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-31 Yuan Zhao, Wanting Qi, Can Huang, Yangzhong Zhou, Qian Wang, Xinping Tian, Mengtao Li, Yan Zhao, Xiaofeng Zeng, Jiuliang Zhao
-
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-31 Anisha B. Dua, Kerri Ford, Stefano Fiore, Dimitrios A. Pappas, Jud C. Janak, Taylor Blachley, Carla Roberts-Toler, Kelechi Emeanuru, Joel M. Kremer, Alan Kivitz
-
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-30 Mark S. Fineman, Timothy E. McAlindon, Christian Lattermann, Christopher J. Swearingen, Sarah Kennedy, Victor A. Lopez, Ismail Simsek, Jeyanesh R. S. Tambiah, Yusuf Yazici
-
Pregnancy Outcomes in Patients with Primary Sjögren’s Syndrome Undergoing Assisted Reproductive Therapy: A Multi-center Retrospective Study Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-24 Minxi Lao, Guangxi Luo, Peiyin Dai, Xiaoxue Zhang, Miaoguan Peng, Yuyi Chen, Hao Ren, Xiaodong Wang, Zhongping Zhan, Dongying Chen
Introduction The aim of this work was to investigate the pregnancy outcomes in infertile patients with primary Sjögren’s syndrome (pSS) undergoing assisted reproductive therapy (ART). Methods A multi-center retrospective study was performed in pregnant women with pSS and ART from five tertiary hospitals from Guangdong Province from 2013 to 2022. Natural planned pregnancy in pSS and healthy people undergoing
-
Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-19 Satoshi Kubo, Yusuke Miyazaki, Yasuyuki Todoroki, Atsushi Nagayasu, Ryuichiro Kanda, Takafumi Aritomi, Satsuki Matsunaga, Masanobu Ueno, Ippei Miyagawa, Koshiro Sonomoto, Kentaro Hanami, Shingo Nakayamada, Yoshiya Tanaka
-
Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1) Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-19 Hideto Kameda, Kohei Hagimori, Yoji Morisaki, Thorsten Holzkämper, Ayako Konomi, Hiroaki Dobashi
-
A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-19 Laura C. Cappelli, George Reed, Dimitrios A. Pappas, Joel M. Kremer
-
Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-15 Natalie Frede, Sonja Hiestand, Franziska Schauer, Dominique Endres, Ludger Tebartz van Elst, Markus Zeisbrich, Nils Craig-Mueller, Stephanie Finzel, Jens Thiel, Reinhard E. Voll, Christoph Schempp, Nils Venhoff
-
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-11 Philip J. Mease, Dafna D. Gladman, Denis Poddubnyy, Soumya D. Chakravarty, May Shawi, Alexa P. Kollmeier, Xie L. Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos
-
Targeting DORIS Remission and LLDAS in SLE: A Review Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-05 Agner R. Parra Sánchez, Ronald F. van Vollenhoven, Eric F. Morand, Ian N. Bruce, Rangi Kandane-Rathnayake, Gudrun Weiss, Raj Tummala, Hussein Al-Mossawi, Alessandro Sorrentino
Remission is the established therapeutic goal for patients with systemic lupus erythematosus (SLE) and is currently defined by the widely adopted Definition Of Remission In SLE (DORIS) criteria. Attainment of remission is rare in the clinical setting, thus an alternative, pragmatic treatment target of low disease activity, as defined by the Lupus Low Disease Activity State (LLDAS), provides a less
-
Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still’s Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-04 Soichiro Adachi, Kaoru Takase-Minegishi, Ayaka Maeda, Hideto Nagai, Nobuyuki Horita, Ryusuke Yoshimi, Yohei Kirino, Hideaki Nakajima
-
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial Rheumatol. Ther. (IF 3.8) Pub Date : 2023-10-04 Cory Perugino, Emma L. Culver, Arezou Khosroshahi, Wen Zhang, Emanuel Della-Torre, Kazuichi Okazaki, Yoshiya Tanaka, Matthias Löhr, Nicolas Schleinitz, Judith Falloon, Dewei She, Daniel Cimbora, John H. Stone
-
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients Rheumatol. Ther. (IF 3.8) Pub Date : 2023-09-27 Rieke Alten, Gerd R. Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Andrew Östör, Khai Jing Ng, Jens Gerwien, Liliana Zaremba-Pechmann, Alan J. M. Brnabic, Bruno Fautrel
-
Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China Rheumatol. Ther. (IF 3.8) Pub Date : 2023-09-27 Xuan Huang, Qing Shu, Xuemei Luo, Weihong Ge, Han Xie, Yujie Zhou
-
Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study Rheumatol. Ther. (IF 3.8) Pub Date : 2023-09-28 Chan-yuan Wu, Qian Wang, Jian Shi, Xiu-ying Zhang, Rong Du, Jie-ruo Gu, Qi-huan Liu, Jiao Yu, Jia-wei Xu, Yan-jie Zhang, Hao Zhu, Meng-tao Li, Xiao-feng Zeng
-
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Rheumatol. Ther. (IF 3.8) Pub Date : 2023-09-25 Alejandro Balsa, Siegfried Wassenberg, Yoshiya Tanaka, Anne Tournadre, Hans-Dieter Orzechowski, Vijay Rajendran, Udo Lendl, Pieter-Jan Stiers, Chris Watson, Roberto Caporali, James Galloway, Patrick Verschueren
-
Association Between Mycophenolate Mofetil Use and Subsequent Infections Among Hospitalized Patients with Systemic Lupus Erythematosus: A Nested Case–Control Study Rheumatol. Ther. (IF 3.8) Pub Date : 2023-09-24 Qingqing Guo, Xueyi Zhang, Siqin Sun, Xiaojun Tang, Wei Shen, Jun Liang, Genhong Yao, Linyu Geng, Shuai Ding, Hongwei Chen, Hong Wang, Bingzhu Hua, Huayong Zhang, Dandan Wang, Xuebing Feng, Lingyun Sun, Ziyi Jin